Latest Safety News

Page 53 of 146
BSA Limited reported a 65% drop in net profit for FY2025 despite a 12% revenue increase, driven by the loss of key contracts and a significant operational overhaul. The company faces near-term unprofitable trading but maintains a strong cash position as it reshapes its business.
Victor Sage
Victor Sage
29 Aug 2025
Prescient Therapeutics has completed a $3 million share placement, bolstering its clinical development programs for innovative cancer treatments including PTX-100 and novel cell therapies.
Ada Torres
Ada Torres
29 Aug 2025
Spacetalk Ltd reports a successful FY25 transformation with revenue up 12%, losses narrowing by 57%, and a new software-led platform set to fuel scalable subscription growth.
Sophie Babbage
Sophie Babbage
29 Aug 2025
SenSen Networks has reported a strong financial turnaround for the year ended June 2025, posting a 26.5% increase in revenue alongside a return to profitability after previous losses.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Spacetalk Limited reported a 12.2% revenue increase to $19.6 million in FY25, driven by recurring mobile subscriptions and device sales, while reducing its net loss by 27.1%. The company secured $3 million in capital post-year-end to support growth amid ongoing going concern uncertainties.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Constellation Technologies Limited has reported a 34% revenue increase and a return to profitability in FY25, driven by strong adoption of its IoT-based food safety solutions across multiple sectors. The company is scaling its innovative Callisto platform and hardware offerings to capture broader market opportunities.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.
Ada Torres
Ada Torres
29 Aug 2025
Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.
Ada Torres
Ada Torres
29 Aug 2025
Careteq Limited has returned to profitability in FY25, reporting a 5.4% revenue increase and a 171% jump in underlying EBITDA, driven by strategic divestments and acquisitions.
Ada Torres
Ada Torres
29 Aug 2025
Regal Asian Investments has commenced on-market share purchases to satisfy its Dividend Reinvestment Plan, pricing shares at or below its recent net tangible asset value of $2.54. This move signals a strategic approach to capital management amid evolving portfolio stewardship.
Claire Turing
Claire Turing
29 Aug 2025
Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.
Ada Torres
Ada Torres
29 Aug 2025
LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.
Ada Torres
Ada Torres
29 Aug 2025